{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:40:11Z","timestamp":1791276011082,"version":"4.1.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2006,6,1]]},"DOI":"10.1038\/nrmicro1419","type":"journal-article","created":{"date-parts":[[2006,5,18]],"date-time":"2006-05-18T12:47:10Z","timestamp":1147956430000},"page":"469-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":235,"title":["Advances in tuberculosis vaccine strategies"],"prefix":"10.1038","volume":"4","author":[{"given":"Yasir A. W.","family":"Skeiky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald C.","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrmicro1419_CR1","first-page":"71","volume":"79","author":"A Kochi","year":"2001","unstructured":"Kochi, A. The global tuberculosis situation and the new control strategy of the World Health Organization 1991. Bull. World Health Organ. 79, 71?75 (2001).","journal-title":"Bull. World Health Organ."},{"key":"BFnrmicro1419_CR2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/clind\/15.3.540","volume":"15","author":"PC Hopewell","year":"1992","unstructured":"Hopewell, P. C. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management and control of tuberculosis. Clin. Infect. Dis. 15, 540?547 (1992).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrmicro1419_CR3","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/0962-8479(94)90113-9","volume":"75","author":"MC Raviglione","year":"1994","unstructured":"Raviglione, M. C. et al. Tuberculosis trends in eastern Europe and the former USSR. Tuber. Lung Dis. 75, 400?416 (1994).","journal-title":"Tuber. Lung Dis."},{"key":"BFnrmicro1419_CR4","first-page":"123","volume":"9","author":"D Maher","year":"2005","unstructured":"Maher, D. et al. Tuberculosis deaths in countries with high HIV prevalence: what is their use as an indicator in tuberculosis programme monitoring and epidemiological surveillance? Int. J. Tuberc. Lung Dis. 9, 123?127 (2005).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFnrmicro1419_CR5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1128\/9781555818357","volume-title":"Tuberculosis: Pathogenesis, Protection, and Control","author":"BR Bloom","year":"1994","unstructured":"Bloom, B. R. & Fine, P. E. In Tuberculosis: Pathogenesis, Protection, and Control (ed. Bloom, B. R.) 531?557 (American Society for Microbiology, Washington DC, 1994)."},{"key":"BFnrmicro1419_CR6","unstructured":"Summary from the 6th Annual Conference of the International Union Against Tuberculosis and Lung Disease. (Chicago, 2001)."},{"key":"BFnrmicro1419_CR7","first-page":"662","volume":"6","author":"LP Ormerod","year":"2002","unstructured":"Ormerod, L. P., Horsfield, N. & Green, R. M. Tuberculosis treatment outcome monitoring: Blackburn 1988?2000. Int. J. Tuberc. Lung Dis. 6, 662?665 (2002).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFnrmicro1419_CR8","first-page":"149","volume":"70","author":"P Sudre","year":"1992","unstructured":"Sudre, P., ten Dam, G. & Kochi, A. Tuberculosis: a global overview of the situation today. Bull. World Health Organ. 70, 149?159 (1992).","journal-title":"Bull. World Health Organ."},{"key":"BFnrmicro1419_CR9","first-page":"213","volume":"72","author":"PJ Dolin","year":"1994","unstructured":"Dolin, P. J., Raviglione, M. C. & Kochi, A. Global tuberculosis incidence and mortality during 1990?2000. Bull. World Health Organ. 72, 213?220 (1994).","journal-title":"Bull. World Health Organ."},{"issue":"Suppl. 1","key":"BFnrmicro1419_CR10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/clind\/15.Supplement_1.S296","volume":"15","author":"P Hopewell","year":"1992","unstructured":"Hopewell, P. et al. Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15 (Suppl. 1), 296?306 (1992).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrmicro1419_CR11","first-page":"47","volume-title":"Tuberculosis: Pathogenesis, Protection, and Control","author":"PG Smith","year":"1994","unstructured":"Smith, P. G. & Moss, A. R. In Tuberculosis: Pathogenesis, Protection, and Control. (ed Bloom, B. R.) 47?59 (American Society for Microbiology, Washington DC, 1994)."},{"issue":"Suppl. 4","key":"BFnrmicro1419_CR12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm1221","volume":"11","author":"SH Kaufmann","year":"2005","unstructured":"Kaufmann, S. H. & McMichael, A. J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nature Med. 11 (Suppl. 4), 33?44 (2005).","journal-title":"Nature Med."},{"key":"BFnrmicro1419_CR13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/S0882-0546(03)00068-9","volume":"18","author":"DM Lewinsohn","year":"2003","unstructured":"Lewinsohn, D. M., Lewinsohn, D. A. & Grotzke, J. E. TB vaccines at the turn of the century: insights into immunity to M. tuberculosis and modern approaches for prevention of an ancient disease. Semin. Respir. Infect. 18, 320?338 (2003).","journal-title":"Semin. Respir. Infect."},{"key":"BFnrmicro1419_CR14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.immunol.19.1.93","volume":"19","author":"JL Flynn","year":"2001","unstructured":"Flynn, J. L. & Chan, J. Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93?129 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrmicro1419_CR15","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJM199612263352604","volume":"335","author":"E Jouanguy","year":"1996","unstructured":"Jouanguy, E. et al. Interferon- \u03b3-receptor deficiency in an infant with fatal bacille Calmette-Gu\u00e9rin infection. N. Engl. J. Med. 335, 1956?1961 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrmicro1419_CR16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/7701","volume":"21","author":"E Jouanguy","year":"1999","unstructured":"Jouanguy, E. et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nature Genet. 21, 370?378 (1999).","journal-title":"Nature Genet."},{"key":"BFnrmicro1419_CR17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14656566.5.3.581","volume":"5","author":"E Toussirot","year":"2004","unstructured":"Toussirot, E. & Wendling, D. The use of TNF-\u03b1 blocking agents in rheumatoid arthritis: an overview. Expert Opin. Pharmacother. 5, 581?594 (2004).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrmicro1419_CR18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1056\/NEJM199902043400507","volume":"340","author":"DV Havlir","year":"1999","unstructured":"Havlir, D. V. & Barnes, P. F. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 340, 367?373 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrmicro1419_CR19","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1084\/jem.178.6.2243","volume":"178","author":"AM Cooper","year":"1993","unstructured":"Cooper, A. M. et al. Disseminated tuberculosis in IFN-\u03b3 gene-disrupted mice. J. Exp. Med. 178, 2243?2247 (1993).","journal-title":"J. Exp. Med."},{"key":"BFnrmicro1419_CR20","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1084\/jem.178.6.2249","volume":"178","author":"JL Flynn","year":"1993","unstructured":"Flynn, J. L. et al. An essential role for IFN-\u03b3 in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249?2254 (1993).","journal-title":"J. Exp. Med."},{"key":"BFnrmicro1419_CR21","doi-asserted-by":"crossref","first-page":"12013","DOI":"10.1073\/pnas.89.24.12013","volume":"89","author":"JL Flynn","year":"1992","unstructured":"Flynn, J. L. et al. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 89, 12013?12017 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1419_CR22","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1128\/IAI.72.3.1685-1692.2004","volume":"72","author":"SC Derrick","year":"2004","unstructured":"Derrick, S. C. et al. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect. Immun. 72, 1685?1692 (2004).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR23","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1002\/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4","volume":"30","author":"LA van Pinxteren","year":"2000","unstructured":"van Pinxteren, L. A. et al. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30, 3689?3698 (2000).","journal-title":"Eur. J. Immunol."},{"key":"BFnrmicro1419_CR24","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/IAI.69.3.1722-1728.2001","volume":"69","author":"M Gonzalez-Juarrero","year":"2001","unstructured":"Gonzalez-Juarrero, M. et al. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 69, 1722?1728 (2001).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/path.1628","volume":"204","author":"T Ulrichs","year":"2004","unstructured":"Ulrichs, T. et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J. Pathol. 204, 217?228 (2004).","journal-title":"J. Pathol."},{"key":"BFnrmicro1419_CR26","doi-asserted-by":"crossref","first-page":"15688","DOI":"10.1073\/pnas.95.26.15688","volume":"95","author":"R Teitelbaum","year":"1998","unstructured":"Teitelbaum, R. et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl Acad. Sci. USA 95, 15688?15693 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1419_CR27","unstructured":"Sadoff, J. Public private partnership approach to vaccine development. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005)."},{"key":"BFnrmicro1419_CR28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20040876","volume":"201","author":"C Bouneaud","year":"2005","unstructured":"Bouneaud, C. et al. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J. Exp. Med. 201, 579?590 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrmicro1419_CR29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ni969","volume":"4","author":"RA Seder","year":"2003","unstructured":"Seder, R. A. & Ahmed, R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nature Immunol. 4, 835?842 (2003).","journal-title":"Nature Immunol."},{"key":"BFnrmicro1419_CR30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/clinids\/20.1.126","volume":"20","author":"TF Brewer","year":"1995","unstructured":"Brewer, T. F. & Colditz, G. A. Relationship between bacille Calmette-Gu\u00e9rin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin. Infect. Dis. 20, 126?135 (1995).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrmicro1419_CR31","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","author":"GA Colditz","year":"1994","unstructured":"Colditz, G. A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698?702 (1994).","journal-title":"JAMA"},{"key":"BFnrmicro1419_CR32","unstructured":"Fine, P. E. M., Carneiro, I. A. M., Milstien, J. B. & Clements, C. J. Issues relating to the use of BCG in immunization programmes (World Health Organization, Geneva, 1999)."},{"key":"BFnrmicro1419_CR33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","volume":"96","author":"GA Colditz","year":"1995","unstructured":"Colditz, G. A. et al. The efficacy of bacillus Calmette-Gu\u00e9rin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96, 29?35 (1995).","journal-title":"Pediatrics"},{"key":"BFnrmicro1419_CR34","first-page":"200","volume":"2","author":"JA Sterne","year":"1998","unstructured":"Sterne, J. A., Rodrigues, L. C. & Guedes, I. N. Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung Dis. 2, 200?207 (1998).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFnrmicro1419_CR35","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1001\/jama.291.17.2086","volume":"291","author":"NE Aronson","year":"2004","unstructured":"Aronson, N. E. et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 291, 2086?2091 (2004).","journal-title":"JAMA"},{"issue":"Suppl. 2","key":"BFnrmicro1419_CR36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/clinids\/11.Supplement_2.S353","volume":"11","author":"PE Fine","year":"1989","unstructured":"Fine, P. E. The BCG story: lessons from the past and implications for the future. Rev. Infect. Dis. 11 (Suppl. 2), 353?359 (1989).","journal-title":"Rev. Infect. Dis."},{"key":"BFnrmicro1419_CR37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0197-2456(94)90042-6","volume":"15","author":"GW Comstock","year":"1994","unstructured":"Comstock, G. W. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin. Trials 15, 247?276 (1994).","journal-title":"Control Clin. Trials"},{"key":"BFnrmicro1419_CR38","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0140-6736(05)67534-4","volume":"366","author":"A Soysal","year":"2005","unstructured":"Soysal, A. et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366, 1443?1451 (2005).","journal-title":"Lancet"},{"key":"BFnrmicro1419_CR39","unstructured":"Tuberculosis Research Centre (ICMR), Chennai. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J. Med. Res. 110, 56?69 (1999)."},{"key":"BFnrmicro1419_CR40","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/IAI.71.4.1672-1679.2003","volume":"71","author":"MA Horwitz","year":"2003","unstructured":"Horwitz, M. A. & Harth, G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71, 1672?1679 (2003).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR41","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1073\/pnas.250480397","volume":"97","author":"MA Horwitz","year":"2000","unstructured":"Horwitz, M. A. et al. Recombinant bacillus Calmette-Gu\u00e9rin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA 97, 13853?13858 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1419_CR42","unstructured":"Hoft, D. F. Results of the 1st Phase I trial of a recombinant BCG TB vaccine (rBCG30). Presented at US?Japan Cooperative Medical Science Program; 40th Tuberculosis and Leprosy Research Conference. (Seattle, Washington, 2005)."},{"key":"BFnrmicro1419_CR43","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1073\/pnas.95.9.5299","volume":"95","author":"J Hess","year":"1998","unstructured":"Hess, J. et al. Mycobacterium bovis bacille Calmette-Gu\u00e9rin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl Acad. Sci. USA 95, 5299?5304 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1419_CR44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/32183","volume":"392","author":"ML Albert","year":"1998","unstructured":"Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86?89 (1998).","journal-title":"Nature"},{"key":"BFnrmicro1419_CR45","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.micinf.2005.03.012","volume":"7","author":"A Nasser Eddine","year":"2005","unstructured":"Nasser Eddine, A. & Kaufmann, S. H. E. Improved protection by recombinant BCG. Microbes Infect. 7, 939?946 (2005).","journal-title":"Microbes Infect."},{"key":"BFnrmicro1419_CR46","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","volume":"115","author":"L Grode","year":"2005","unstructured":"Grode, L. et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Gu\u00e9rin mutants that secrete listeriolysin. J. Clin. Invest. 115, 2472?2479 (2005).","journal-title":"J. Clin. Invest."},{"key":"BFnrmicro1419_CR47","unstructured":"Kaufmann, S. H. E. Rational vaccine design against tuberculosis. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005)."},{"key":"BFnrmicro1419_CR48","unstructured":"Laufer, A. Managing the transition from academic vaccine research to license oriented development. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005)."},{"key":"BFnrmicro1419_CR49","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/iai.60.7.2710-2717.1992","volume":"60","author":"DA Portnoy","year":"1992","unstructured":"Portnoy, D. A. et al. Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells. Infect. Immun. 60, 2710?2717 (1992).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR50","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1164\/ajrccm.164.12.2106093","volume":"164","author":"KM Edwards","year":"2001","unstructured":"Edwards, K. M. et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 164, 2213?2219 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrmicro1419_CR51","unstructured":"Kernodle, D. S. Pro-apoptotic BCG vaccine that enhances cellular immune responses and reduces tissue damage. Aeras Global TB Vaccine Foundation Scott Thaler Lecture Series. (Bethesda, Maryland, 2004)."},{"key":"BFnrmicro1419_CR52","unstructured":"Jacobs, B. Live attenuated vaccines for TB: Mining the immune evasion function of the tubercle bacillus. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005)."},{"key":"BFnrmicro1419_CR53","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/79470","volume":"18","author":"MA Chattergoon","year":"2000","unstructured":"Chattergoon, M. A. et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nature Biotechnol. 18, 974?979 (2000).","journal-title":"Nature Biotechnol."},{"key":"BFnrmicro1419_CR54","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.277.5327.818","volume":"277","author":"JP Sheridan","year":"1997","unstructured":"Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818?821 (1997).","journal-title":"Science"},{"key":"BFnrmicro1419_CR55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1438-4221(00)80083-1","volume":"290","author":"R Brosch","year":"2000","unstructured":"Brosch, R. et al. Comparative genomics of the mycobacteria. Int. J. Med. Microbiol. 290, 143?152 (2000).","journal-title":"Int. J. Med. Microbiol."},{"key":"BFnrmicro1419_CR56","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1128\/jb.178.5.1274-1282.1996","volume":"178","author":"GG Mahairas","year":"1996","unstructured":"Mahairas, G. G. et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178, 1274?1282 (1996).","journal-title":"J. Bacteriol."},{"key":"BFnrmicro1419_CR57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nm859","volume":"9","author":"AS Pym","year":"2003","unstructured":"Pym, A. S. et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Med. 9, 533?539 (2003).","journal-title":"Nature Med."},{"key":"BFnrmicro1419_CR58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2958.2002.03237.x","volume":"46","author":"AS Pym","year":"2002","unstructured":"Pym, A. S. et al. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol. Microbiol. 46, 709?717 (2002).","journal-title":"Mol. Microbiol."},{"key":"BFnrmicro1419_CR59","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","volume":"284","author":"MA Behr","year":"1999","unstructured":"Behr, M. A. et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284, 1520?1523 (1999).","journal-title":"Science"},{"key":"BFnrmicro1419_CR60","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2958.1999.01383.x","volume":"32","author":"SV Gordon","year":"1999","unstructured":"Gordon, S. V. et al. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol. Microbiol. 32, 643?645 (1999).","journal-title":"Mol. Microbiol."},{"key":"BFnrmicro1419_CR61","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1101\/gr.152900","volume":"10","author":"H Salamon","year":"2000","unstructured":"Salamon, H. et al. Detection of deleted genomic DNA using a semiautomated computational analysis of GeneChip data. Genome Res. 10, 2044?2054 (2000).","journal-title":"Genome Res."},{"key":"BFnrmicro1419_CR62","volume-title":"New Live Mycobacterial Vaccines: Defining Essential Steps Towards Clinical Development","author":"AT Kamath","year":"2004","unstructured":"Kamath, A. T. et al. In New Live Mycobacterial Vaccines: Defining Essential Steps Towards Clinical Development. (WHO, Geneva, Switzerland, 2004)."},{"key":"BFnrmicro1419_CR63","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1128\/JCM.42.1.212-219.2004","volume":"42","author":"CY Soto","year":"2004","unstructured":"Soto, C. Y. et al. IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks. J. Clin. Microbiol. 42, 212?219 (2004).","journal-title":"J. Clin. Microbiol."},{"key":"BFnrmicro1419_CR64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2958.2001.02500.x","volume":"41","author":"E Perez","year":"2001","unstructured":"Perez, E. et al. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol. Microbiol. 41, 179?187 (2001).","journal-title":"Mol. Microbiol."},{"key":"BFnrmicro1419_CR65","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm0396-334","volume":"2","author":"I Guleria","year":"1996","unstructured":"Guleria, I. et al. Auxotrophic vaccines for tuberculosis. Nature Med. 2, 334?337 (1996).","journal-title":"Nature Med."},{"key":"BFnrmicro1419_CR66","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/IAI.69.2.1442-1150.2001","volume":"69","author":"DA Smith","year":"2001","unstructured":"Smith, D. A. et al. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Immun. 69, 1142?1150 (2001).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR67","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1128\/IAI.67.6.2867-2873.1999","volume":"67","author":"M Jackson","year":"1999","unstructured":"Jackson, M. et al. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. 67, 2867?2873 (1999).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR68","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1128\/IAI.73.2.1196-1203.2005","volume":"73","author":"VK Sambandamurthy","year":"2005","unstructured":"Sambandamurthy, V. K. et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect. Immun. 73, 1196?1203 (2005).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR69","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/nm765","volume":"8","author":"VK Sambandamurthy","year":"2002","unstructured":"Sambandamurthy, V. K. et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nature Med. 8, 1171?1174 (2002).","journal-title":"Nature Med."},{"key":"BFnrmicro1419_CR70","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.micinf.2005.04.001","volume":"7","author":"VK Sambandamurthy","year":"2005","unstructured":"Sambandamurthy, V. K. & Jacobs, W. R. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 7, 955?961 (2005).","journal-title":"Microbes Infect."},{"key":"BFnrmicro1419_CR71","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1128\/iai.57.8.2481-2488.1989","volume":"57","author":"AB Andersen","year":"1989","unstructured":"Andersen, A. B. & Hansen, E. B. Structure and mapping of antigenic domains of protein antigen b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis. Infect. Immun. 57, 2481?2488 (1989).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1128\/iai.59.1.372-382.1991","volume":"59","author":"S Nagai","year":"1991","unstructured":"Nagai, S. et al. Isolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosis. Infect. Immun. 59, 372?382 (1991).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR73","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0923-2508(91)90097-T","volume":"142","author":"DB Young","year":"1991","unstructured":"Young, D. B. & Garbe, T. R. Lipoprotein antigens of Mycobacterium tuberculosis. Res. Microbiol. 142, 55?65 (1991).","journal-title":"Res. Microbiol."},{"key":"BFnrmicro1419_CR74","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.4049\/jimmunol.154.7.3359","volume":"154","author":"P Andersen","year":"1995","unstructured":"Andersen, P. et al. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J. Immunol. 154, 3359?3372 (1995).","journal-title":"J. Immunol."},{"key":"BFnrmicro1419_CR75","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/IAI.68.1.214-220.2000","volume":"68","author":"RL Skjot","year":"2000","unstructured":"Skjot, R. L. et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect. Immun. 68, 214?220 (2000).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR76","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.191.3.551","volume":"191","author":"MR Alderson","year":"2000","unstructured":"Alderson, M. R. et al. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4+ T cells. J. Exp. Med. 191, 551?560 (2000).","journal-title":"J. Exp. Med."},{"key":"BFnrmicro1419_CR77","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1128\/JCM.38.9.3285-3290.2000","volume":"38","author":"DC Dillon","year":"2000","unstructured":"Dillon, D. C. et al. Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J. Clin. Microbiol. 38, 3285?3290 (2000).","journal-title":"J. Clin. Microbiol."},{"key":"BFnrmicro1419_CR78","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.4049\/jimmunol.165.12.7140","volume":"165","author":"YA Skeiky","year":"2000","unstructured":"Skeiky, Y. A. et al. T-cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J. Immunol. 165, 7140?7149 (2000).","journal-title":"J. Immunol."},{"key":"BFnrmicro1419_CR79","first-page":"71","volume-title":"Tuberculosis and the Tubercle Bacillus","author":"S Laal","year":"2005","unstructured":"Laal, S. & Skeiky, Y. A. W. In Tuberculosis and the Tubercle Bacillus. (eds Cole, S. T. et al.) 71?83 (American Society for Microbiology Press, Washington DC, 2005)."},{"key":"BFnrmicro1419_CR80","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1128\/IAI.67.8.3998-4007.1999","volume":"67","author":"YA Skeiky","year":"1999","unstructured":"Skeiky, Y. A. et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect. Immun. 67, 3998?4007 (1999).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR81","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/IAI.67.6.2941-2950.1999","volume":"67","author":"DC Dillon","year":"1999","unstructured":"Dillon, D. C. et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect. Immun. 67, 2941?2950 (1999).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR82","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/1615-9861(200104)1:4<574::AID-PROT574>3.0.CO;2-8","volume":"1","author":"BA Covert","year":"2001","unstructured":"Covert, B. A. et al. The application of proteomics in defining the T-cell antigens of Mycobacterium tuberculosis. Proteomics 1, 574?586 (2001).","journal-title":"Proteomics"},{"key":"BFnrmicro1419_CR83","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1002\/elps.200305601","volume":"24","author":"J Mattow","year":"2003","unstructured":"Mattow, J. et al. Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M. bovis BCG Copenhagen. Electrophoresis 24, 3405?3420 (2003).","journal-title":"Electrophoresis"},{"key":"BFnrmicro1419_CR84","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1128\/IAI.72.11.6471-6479.2004","volume":"72","author":"HJ Mollenkopf","year":"2004","unstructured":"Mollenkopf, H. J. et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime?Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun. 72, 6471?6479 (2004).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR85","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm0896-893","volume":"2","author":"K Huygen","year":"1996","unstructured":"Huygen, K. et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med. 2, 893?898 (1996).","journal-title":"Nature Med."},{"key":"BFnrmicro1419_CR86","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1128\/IAI.66.6.2951-2959.1998","volume":"66","author":"SL Baldwin","year":"1998","unstructured":"Baldwin, S. L. et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66, 2951?2959 (1998).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR87","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1128\/IAI.70.10.5446-5453.2002","volume":"70","author":"RL Skjot","year":"2002","unstructured":"Skjot, R. L. et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect. Immun. 70, 5446?5453 (2002).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR88","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","volume":"172","author":"YA Skeiky","year":"2004","unstructured":"Skeiky, Y. A. et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172, 7618?7628 (2004).","journal-title":"J. Immunol."},{"key":"BFnrmicro1419_CR89","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1128\/IAI.69.5.2773-2778.2001","volume":"69","author":"A Weinrich Olsen","year":"2001","unstructured":"Weinrich Olsen, A. et al. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and ESAT-6. Infect. Immun. 69, 2773?2778 (2001).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR90","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1128\/IAI.72.11.6622-6632.2004","volume":"72","author":"L Brandt","year":"2004","unstructured":"Brandt, L. et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72, 6622?6632 (2004).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR91","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/1521-4141(200006)30:6<1724::AID-IMMU1724>3.0.CO;2-A","volume":"30","author":"AW Olsen","year":"2000","unstructured":"Olsen, A. W. et al. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur. J. Immunol. 30, 1724?1732 (2000).","journal-title":"Eur. J. Immunol."},{"key":"BFnrmicro1419_CR92","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/IAI.72.10.6148-6150.2004","volume":"72","author":"AW Olsen","year":"2004","unstructured":"Olsen, A. W. et al. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72, 6148?6150 (2004).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR93","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/jama.286.14.1740","volume":"286","author":"GH Mazurek","year":"2001","unstructured":"Mazurek, G. H. et al. Comparison of a whole-blood IFN-\u03b3 assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286, 1740?1747 (2001).","journal-title":"JAMA"},{"key":"BFnrmicro1419_CR94","first-page":"15","volume":"52","author":"GH Mazurek","year":"2003","unstructured":"Mazurek, G. H. & Villarino, M. E. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 52, 15?18 (2003).","journal-title":"MMWR Recomm. Rep."},{"key":"BFnrmicro1419_CR95","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.4049\/jimmunol.174.10.6332","volume":"174","author":"J Dietrich","year":"2005","unstructured":"Dietrich, J. et al. Exchanging ESAT-6 with TB10. 4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT-6-based sensitive monitoring of vaccine efficacy. J. Immunol. 174, 6332?6339 (2005).","journal-title":"J. Immunol."},{"key":"BFnrmicro1419_CR96","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1128\/IAI.69.4.2714-2717.2001","volume":"69","author":"JV Brooks","year":"2001","unstructured":"Brooks, J. V. et al. Boosting vaccine for tuberculosis. Infect. Immun. 69, 2714?2717 (2001).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR97","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.171.3.1602","volume":"171","author":"NP Goonetilleke","year":"2003","unstructured":"Goonetilleke, N. P. et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Gu\u00e9rin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171, 1602?1609 (2003).","journal-title":"J. Immunol."},{"key":"BFnrmicro1419_CR98","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","volume":"173","author":"J Wang","year":"2004","unstructured":"Wang, J. et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173, 6357?6365 (2004).","journal-title":"J. Immunol."},{"key":"BFnrmicro1419_CR99","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","volume":"77","author":"R Vogels","year":"2003","unstructured":"Vogels, R. et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of pre-existing adenovirus immunity. J. Virol. 77, 8263?8271 (2003).","journal-title":"J. Virol."},{"key":"BFnrmicro1419_CR100","unstructured":"Havenga et al. Novel replication-incompetent adenoviral B-group vectors. J. Virol. (In the press)."},{"key":"BFnrmicro1419_CR101","unstructured":"Hone, D. Optimization of nucleic acid vaccine delivery by bacterial vectors. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005)."},{"key":"BFnrmicro1419_CR102","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.20030846","volume":"198","author":"D Schnappinger","year":"2003","unstructured":"Schnappinger, D. et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J. Exp. Med. 198, 693?704 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnrmicro1419_CR103","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1084\/jem.20030205","volume":"198","author":"MI Voskuil","year":"2003","unstructured":"Voskuil, M. I. et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 198, 705?713 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnrmicro1419_CR104","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1128\/IAI.71.10.5831-5844.2003","volume":"71","author":"SV Capuano","year":"2003","unstructured":"Capuano, S. V. et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71, 5831?5844 (2003).","journal-title":"Infect. Immun."},{"key":"BFnrmicro1419_CR105","unstructured":"Hussey, G., Hawkridge, T., Geiter, L. & Hanekom, W. Presented at TB vaccines for the world (April 19?21, Vienna, Austria, 2006)."},{"key":"BFnrmicro1419_CR106","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","volume":"10","author":"H McShane","year":"2004","unstructured":"McShane, H. et al. Recombinant MVA85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10, 1240?1244 (2004).","journal-title":"Nature Med."},{"key":"BFnrmicro1419_CR107","volume-title":"Presented at TB vaccines for the world","author":"K Radosevic","year":"2006","unstructured":"Radosevic, K. et al. Presented at TB vaccines for the world (April 19?21, Vienna, Austria, 2006)."}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrmicro1419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrmicro1419","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrmicro1419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:39:09Z","timestamp":1744274349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrmicro1419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6,1]]}},"alternative-id":["BFnrmicro1419"],"URL":"https:\/\/doi.org\/10.1038\/nrmicro1419","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,1]]},"assertion":[{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}